Stock Price Forecast

May 24, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Antares Pharma Inc chart...

About the Company

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

CEO

Robert Apple

Exchange

NASDAQ

Website

www.antarespharma.com

$184M

Total Revenue

185

Employees

$978M

Market Capitalization

21.50

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ATRS News

Teva gains U.S. approval for generic version of osteoporosis injection

5mon ago, source: Hosted on MSN

Teva's (TEVA) generic equivalent of Forteo uses multi-dose pen device from Antares Pharma, a wholly owned subsidiary of Halozyme Therapeutics (HALO). Antares and Teva are parties to an exclusive ...

Global Insulin Delivery Pens Market Poised for Remarkable Growth, Reaching US$ 48.6 Billion by 2032

3d ago, source: Future Market Insights

Insulin Delivery Pens Market forecasts a robust CAGR of 8.0%, propelling the market to a valuation of US$ 48.6 Billion by ...

Vincerx Pharma Inc Ordinary Shares VINC

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

VIRX Viracta Therapeutics, Inc.

2d ago, source: Seeking Alpha

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product ...

Top 10 Drug Delivery Technologies Market Size and Scope, Industry snapshot, Leading Companies and Opportunity Analysis by 2032

7d ago, source: Taiwan News

Growing need for effective delivery of novel biopharmaceuticals and pharmaceutical coupled with innovation in drug delivery ...

BridgeBio Pharma, Inc. (BBIO)

6d ago, source: Yahoo Finance

PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

Bioidentical Estradiol Gel for Hormone Therapy in Menopause

7d ago, source: Medscape

Elestrin™ (transdermal estradiol gel) is a new gel formulation of bioidentical estradiol developed by BioSante Pharmaceuticals, Inc. (IL ... for estradiol by Antares Pharma and BioSante.

Lantern Pharma Inc. (LTRN)

8d ago, source: Yahoo Finance

DALLAS, April 22, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and ...

SPRO Spero Therapeutics, Inc.

2d ago, source: Seeking Alpha

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical ... It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to ...

Oncology Pharma Inc ONPH

8d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...